Leader in nucleic acid diagnostics selects clinivation WorldView as its most comprehensive, authoritative resource for building its medical product submissions and registrations worldwide.
Natick, MA, September 28, 2007 – clinivation, Inc. announced today that Gen-Probe, Inc. (NASDAQ: GPRO) has selected clinivation WorldView® Online Regulatory Intelligence web service.
“We are pleased to add Gen-Probe to the growing list of diagnostic companies who clearly see the value of one comprehensive, authoritative source for worldwide regulatory intelligence,” remarked Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions. “Gen-Probe will now have unlimited access to ever-changing regulations in one centralized place,” he continued.
Clinivation WorldView is your most comprehensive, authoritative, and up-to-date resource for building all of your medical device submissions and registrations worldwide. Clinivation WorldView also interoperates with clinivation Global® enterprise software to make building and tracking medical device submissions and registrations easier than ever before.
About Gen-Probe, Inc.
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 20 years of NAT expertise, and received the 2004 National Medal of Technology, America’s highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.
For more information, please go to www.gen-probe.com.